Which has better valuation & earnings, VRX or MRV?

Nuvo Pharmaceuticals has higher revenue and earnings than Valeant Pharmaceuticals International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valeant Pharmaceuticals International N/A N/A N/A N/A N/A Nuvo Pharmaceuticals C$8.72B 3.64 C$15.17M C$2.91 12.15

Which has stronger earnings & valuation, MRV or APHA?

Nuvo Pharmaceuticals has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvo Pharmaceuticals C$8.72B 3.64 C$15.17M C$2.91 12.15 Aphria C$611.06M 0.00 -C$637.39M -C$2.01 N/A

Do analysts rate BHC or MRV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuvo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer MRV or CRON?

Cronos Group has a consensus target price of C$4.75, suggesting a potential upside of 21.17%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Nuvo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, MRV or CRON?

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvo Pharmaceuticals C$8.72B 3.64 C$15.17M C$2.91 12.15 Cronos Group C$159.54M 9.18 -C$32.78M N/A N/A

Do analysts rate MRV or GUD?

Knight Therapeutics has a consensus target price of C$9.50, indicating a potential upside of 1.60%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than Nuvo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Nuvo Pharmaceuticals (MRV) Competitors

C$35.37 +4.87 (+15.97%)

As of 12:10 PM Eastern

Compare

MRV vs. VRX, APHA, BHC, CRON, and GUD

Should you buy Nuvo Pharmaceuticals stock or one of its competitors? MarketBeat compares Nuvo Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvo Pharmaceuticals include Valeant Pharmaceuticals International (VRX), Aphria (APHA), Bausch Health Companies (BHC), Cronos Group (CRON), and Knight Therapeutics (GUD).

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International (TSE:VRX) and Nuvo Pharmaceuticals (TSE:MRV) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Valeant Pharmaceuticals International's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Valeant Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valeant Pharmaceuticals International	N/A	N/A	N/A
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Valeant Pharmaceuticals International's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Valeant Pharmaceuticals International	Neutral
Nuvo Pharmaceuticals	Neutral

Nuvo Pharmaceuticals has higher revenue and earnings than Valeant Pharmaceuticals International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
Nuvo Pharmaceuticals	C$8.72B	3.64	C$15.17M	C$2.91	12.15

Summary

Nuvo Pharmaceuticals beats Valeant Pharmaceuticals International on 6 of the 6 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Aphria?

Nuvo Pharmaceuticals (TSE:MRV) and Aphria (TSE:APHA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Nuvo Pharmaceuticals has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals	C$8.72B	3.64	C$15.17M	C$2.91	12.15
Aphria	C$611.06M	0.00	-C$637.39M	-C$2.01	N/A

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Aphria's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Aphria's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%
Aphria	N/A	N/A	N/A

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company	Overall Sentiment
Nuvo Pharmaceuticals	Neutral
Aphria	Neutral

Summary

Nuvo Pharmaceuticals beats Aphria on 9 of the 9 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Nuvo Pharmaceuticals (TSE:MRV) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bausch Health Companies has a beta of 0.973491, meaning that its share price is 3% less volatile than the broader market. Comparatively, Nuvo Pharmaceuticals has a beta of 0.917796, meaning that its share price is 8% less volatile than the broader market.

Nuvo Pharmaceuticals has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	C$10.85B	0.32	-C$125.65M	-C$2.94	N/A
Nuvo Pharmaceuticals	C$8.72B	3.64	C$15.17M	C$2.91	12.15

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Bausch Health Companies' net margin of -12.02%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Bausch Health Companies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-12.02%	87.57%	4.16%
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%

10.5% of Bausch Health Companies shares are held by institutional investors. Comparatively, 1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by insiders. Comparatively, 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Bausch Health Companies had 16 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 16 mentions for Bausch Health Companies and 0 mentions for Nuvo Pharmaceuticals. Bausch Health Companies' average media sentiment score of 0.09 beat Nuvo Pharmaceuticals' score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the media.

Company	Overall Sentiment
Bausch Health Companies	Neutral
Nuvo Pharmaceuticals	Neutral

Summary

Bausch Health Companies and Nuvo Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Cronos Group?

Nuvo Pharmaceuticals (TSE:MRV) and Cronos Group (TSE:CRON) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.4% of Cronos Group shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by insiders. Comparatively, 46.4% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvo Pharmaceuticals has a beta of 0.917796, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.126226, indicating that its stock price is 13% more volatile than the broader market.

Cronos Group has a consensus target price of C$4.75, suggesting a potential upside of 21.17%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Nuvo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Cronos Group's average media sentiment score of 0.40 beat Nuvo Pharmaceuticals' score of 0.00 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvo Pharmaceuticals	Neutral
Cronos Group	Neutral

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Cronos Group's net margin of -1.29%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%
Cronos Group	-1.29%	-0.19%	-3.73%

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals	C$8.72B	3.64	C$15.17M	C$2.91	12.15
Cronos Group	C$159.54M	9.18	-C$32.78M	N/A	N/A

Summary

Cronos Group beats Nuvo Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Knight Therapeutics?

Nuvo Pharmaceuticals (TSE:MRV) and Knight Therapeutics (TSE:GUD) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

In the previous week, Knight Therapeutics had 1 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for Nuvo Pharmaceuticals. Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nuvo Pharmaceuticals	Neutral
Knight Therapeutics	Neutral

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Knight Therapeutics' net margin of 1.10%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%
Knight Therapeutics	1.10%	0.73%	0.51%

Nuvo Pharmaceuticals has higher revenue and earnings than Knight Therapeutics. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals	C$8.72B	3.64	C$15.17M	C$2.91	12.15
Knight Therapeutics	C$510.45M	1.80	-C$30.73M	C$0.06	155.83

Nuvo Pharmaceuticals has a beta of 0.917796, meaning that its share price is 8% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.206788, meaning that its share price is 121% less volatile than the broader market.

Knight Therapeutics has a consensus target price of C$9.50, indicating a potential upside of 1.60%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than Nuvo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. Comparatively, 22.7% of Knight Therapeutics shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Nuvo Pharmaceuticals beats Knight Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Nuvo Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRV vs. The Competition

Export

Metric	Nuvo Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$31.75B	C$11.50B	C$6.81B	C$12.42B
Dividend Yield	0.03%	2.74%	2.60%	6.20%
P/E Ratio	12.15	791.51	279.92	33.96
Price / Sales	3.64	943.66	647.84	9.55
Price / Cash	0.23	14.82	28.64	82.29
Price / Book	47.16	10.39	11.11	4.43
Net Income	C$15.17M	C$2.80B	C$3.48B	C$299.09M
7 Day Performance	24.76%	1.61%	2.04%	1.16%
1 Month Performance	-15.28%	-3.16%	-3.16%	-0.54%
1 Year Performance	N/A	155.11%	63.65%	34.74%

Nuvo Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRV Nuvo Pharmaceuticals	N/A	C$35.37 +16.0%	N/A	N/A	C$31.75B	C$8.72B	12.15	N/A	Gap Up
VRX Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	C$10.76B	N/A	N/A	N/A
APHA Aphria	N/A	N/A	N/A	N/A	C$5.24B	C$611.06M	N/A	1,200
BHC Bausch Health Companies	0.8585 of 5 stars	C$8.43 +28.5%	N/A	+22.3%	C$3.15B	C$10.53B	N/A	19,900	Earnings Report High Trading Volume
CRON Cronos Group	2.2525 of 5 stars	C$4.06 +0.5%	C$4.75 +17.0%	+46.8%	C$1.52B	C$159.54M	N/A	450

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:MRV) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvo Pharmaceuticals (MRV) Competitors

MRV vs. VRX, APHA, BHC, CRON, and GUD

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Summary

How does Nuvo Pharmaceuticals compare to Aphria?

Summary

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Summary

How does Nuvo Pharmaceuticals compare to Cronos Group?

Summary

How does Nuvo Pharmaceuticals compare to Knight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRV vs. The Competition

Nuvo Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvo Pharmaceuticals (MRV) Competitors

MRV vs. VRX, APHA, BHC, CRON, and GUD

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Is VRX or MRV more profitable?

Do institutionals & insiders believe in VRX or MRV?

Does the media refer more to VRX or MRV?

Which has better valuation & earnings, VRX or MRV?

Summary

How does Nuvo Pharmaceuticals compare to Aphria?

Which has stronger earnings & valuation, MRV or APHA?

Do institutionals and insiders hold more shares of MRV or APHA?

Is MRV or APHA more profitable?

Does the media favor MRV or APHA?

Summary

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Do analysts rate BHC or MRV?

Which has more risk and volatility, BHC or MRV?

Which has preferable earnings and valuation, BHC or MRV?

Is BHC or MRV more profitable?

Do insiders & institutionals believe in BHC or MRV?

Does the media favor BHC or MRV?

Summary

How does Nuvo Pharmaceuticals compare to Cronos Group?

Do institutionals and insiders have more ownership in MRV or CRON?

Which has more risk & volatility, MRV or CRON?

Do analysts prefer MRV or CRON?

Does the media refer more to MRV or CRON?

Is MRV or CRON more profitable?

Which has stronger earnings & valuation, MRV or CRON?

Summary

How does Nuvo Pharmaceuticals compare to Knight Therapeutics?

Does the media favor MRV or GUD?

Is MRV or GUD more profitable?

Which has preferable valuation & earnings, MRV or GUD?

Which has more volatility & risk, MRV or GUD?

Do analysts rate MRV or GUD?

Do institutionals & insiders hold more shares of MRV or GUD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRV vs. The Competition

Nuvo Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools